Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


AbbVie outlines revised $51.3B Shire offer

Wednesday, July 9, 2014 12:08 PM

AbbVie has outlined its revised proposal for Shire of $38.38 in cash and 0.8568 ordinary shares of New AbbVie for each Shire share (the Fourth Proposal). The Fourth Proposal represents an indicative value of $87.49 as of July 7, for a total of approximately $51.3 billion.

More... »

WIRB Copernicus Group

Mariel Therapeutics to acquire Stryker's organ fibrosis assets

Wednesday, July 9, 2014 12:06 PM

Mariel Therapeutics, a clinical stage biopharmaceutical company, has entered into a definitive agreement to acquire Stryker's Bone Morphogenetic Protein-7 (BMP-7) assets for the potential treatment of osteoarthritis (OA), chronic kidney disease (CKD) and other organ fibrosis conditions including lupus and obesity.

More... »

CRF Health eCOA webinar series

Report: cancer immunotherapy market to hit $9B globally by 2022

Wednesday, July 9, 2014 12:05 PM

Decision Resources Group reports the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the U.S., France, Germany, Italy, Spain, U.K. and Japan.

More... »

AstraZeneca, Max Planck Institute to create satellite chemistry unit

Wednesday, July 9, 2014 12:03 PM

The Max Planck Institute of Molecular Physiology (MPI), Germany, will establish a satellite unit in cardiovascular and metabolic disease (CVMD) with AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

More... »

Portola, Daiichi Sankyo to collaborate on andexanet alfa study

Wednesday, July 9, 2014 12:01 PM

Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in phase III registration studies with Daiichi Sankyo's Factor Xa inhibitor edoxaban. Portola's original collaboration agreement with Daiichi Sankyo, announced in June 2013, covered the conduct of a phase II proof-of-concept study, for which results are anticipated later this year.

More... »

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials

Monday, July 7, 2014 10:08 AM

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials after a comprehensive study of all of the clinical trials for Alzheimer’s drugs in the U.S. highlighted a very high failure rate of the drugs being tested. The study, published in Alzheimer’s Research and Therapy, found that 99.6% of trials of potential Alzheimer’s treatments aimed at preventing, curing or improving the symptoms of the disease failed or were discontinued.

More... »

Bio-Techne to acquire Novus Biologicals

Monday, July 7, 2014 10:06 AM

Bio-Techne has acquired Novus Biologicals for $60 million in cash. Novus Biologicals is a Littleton, Colorado-based supplier of outsourced and in-house developed antibodies and other reagents for life science research. The transaction was financed with cash on hand.

More... »

Parexel International acquires Atlas Medical Services

Monday, July 7, 2014 10:05 AM

Global CRO Parexel International has acquired Atlas Medical Services, a provider of clinical research services in Turkey, the Middle East and North Africa.

More... »

AMRI completes acquisition of Oso Biopharmaceuticals Manufacturing

Friday, July 4, 2014 10:00 PM

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners.

More... »

Actavis completes acquisition of Furiex Pharmaceuticals

Friday, July 4, 2014 08:00 AM

Forest Laboratories, a subsidiary of Actavis, has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs